Chatterjee S K, Tripathi P K, Chakraborty M, Yannelli J, Wang H, Foon K A, Maier C C, Blalock J E, Bhattacharya-Chatterjee M
Department of Internal Medicine, and Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536-0096, USA.
Cancer Res. 1998 Mar 15;58(6):1217-24.
Our goal was to use carcinoembryonic antigen (CEA) as a target for immunotherapy in CEA-positive cancer patients who are all immune tolerant to the native antigen. We isolated and characterized an anti-idiotype monoclonal antibody 3H1, which mimics a distinct and specific epitope of the Mr 180,000 CEA and can be used as a surrogate for CEA. In Phase Ib clinical trials in a group of 23 advanced colorectal cancer patients, 3H1 induced both humoral and cellular anti-3H1 responses, as well as anti-CEA immunity. To study the cellular immunity invoked by 3H1 at the molecular level, we have cloned and sequenced the cDNAs encoding the variable heavy and light chains of 3H1 and deduced the amino acid sequences of the encoded proteins. To identify any cross-reactive peptides of 3H1 and CEA, we compared the amino acid sequences of 3H1 with those of CEA and found several regions of homology in 3H1 heavy and light chain variable domains, as well as in the framework regions. To search for potential cross-reactive T-cell epitopes, a number of peptides were synthesized based on 3H1/CEA homology and were used as stimulants in cell proliferation assays, using peripheral blood mononuclear cells from a group of 3H1-immunized CEA-positive cancer patients in the adjuvant setting. Two partially homologous peptides, designated LCD-2 (from 3H1) and CEA-B (from CEA), were identified in 10 of 21 adjuvant patients by strong proliferation responses (stimulation index, 3-50-fold), which were extensively studied in five of these individuals over an extended period of time (12-24 months). We saw no correlation with the MHC class I haplotype of the patients. Analysis of the subtype of the responding T cells demonstrated that primarily CD4+ T cells were stimulated by both 3H1 and 3H1-derived peptides. Interleukin 2, interleukin 4, and IFN-gamma were assayed in the culture medium of peripheral blood mononuclear cells stimulated with 3H1, CEA, and LCD-2 to determine the T-cell helper subset induced by these stimulants. The in vitro responses were mainly associated with secretion of IFN-gamma, which suggested that the induced T cells were most likely CD4+ Th1 type. Future studies will include the design of second-generation LCD-2 and CEA peptides to further enhance antigenicity, to characterize the responding T-cell populations more fully, and to test refined peptides for immunogenicity.
我们的目标是将癌胚抗原(CEA)作为免疫疗法的靶点,用于对天然抗原均具有免疫耐受性的CEA阳性癌症患者。我们分离并鉴定了一种抗独特型单克隆抗体3H1,它模拟了分子量为180,000的CEA的一个独特且特异的表位,可作为CEA的替代物。在一组23例晚期结直肠癌患者的Ib期临床试验中,3H1诱导了体液和细胞抗3H1反应以及抗CEA免疫。为了在分子水平上研究3H1引发的细胞免疫,我们克隆并测序了编码3H1重链和轻链可变区的cDNA,并推导了编码蛋白的氨基酸序列。为了鉴定3H1和CEA的任何交叉反应性肽段,我们将3H1的氨基酸序列与CEA的进行了比较,发现在3H1重链和轻链可变区以及框架区有几个同源区域。为了寻找潜在的交叉反应性T细胞表位,基于3H1/CEA同源性合成了一些肽段,并将其用作细胞增殖试验的刺激剂,使用来自一组在辅助治疗中接种了3H1的CEA阳性癌症患者的外周血单个核细胞。在21例辅助治疗患者中的10例中,通过强烈的增殖反应(刺激指数为3至50倍)鉴定出了两个部分同源的肽段,分别命名为LCD-2(来自3H1)和CEA-B(来自CEA),并在其中5例个体中进行了长达12至24个月的广泛研究。我们未发现与患者的MHC I类单倍型相关。对反应性T细胞亚型的分析表明,主要是CD4 + T细胞受到3H1和3H1衍生肽段的刺激。在用3H1、CEA和LCD-2刺激的外周血单个核细胞培养基中检测白细胞介素2、白细胞介素4和干扰素-γ,以确定这些刺激剂诱导的T细胞辅助亚群。体外反应主要与干扰素-γ的分泌相关,这表明诱导的T细胞很可能是CD4 + Th1型。未来的研究将包括设计第二代LCD-2和CEA肽段,以进一步增强抗原性,更全面地表征反应性T细胞群体,并测试精制肽段的免疫原性。